Aug 10, 2023 / 03:00PM GMT
Edward Nash - Canaccord Genuity Group Inc. - Analyst
Thank you for joining us. My name is Edward Nash. I am a Senior Analyst on the Biotech team here at Canaccord Genuity.
It is my pleasure to have with us today the management team of Cardiol Therapeutics. Cardiol is a name that we currently cover with a buy rating. And it's one of the, I think, more interesting names for sure, and have a limited number of names, which makes it even more interesting, I believe, in the cardiology space.
With us, we have David Elsley, who is the President and Chief Executive Officer; and Dr. Andrew Hammer, who is the Chief Medical Officer. And I'll have David give the presentation, and then we'll have perhaps a little bit of time after for any Q&A. With that, I'll turn it over to you, David.
David Elsley - Cardiol Therapeutics Inc. - President, CEO & Director
Okay. Thanks, Edward, and good morning, everyone. It's a great pleasure to have the opportunity to present Cardiol Therapeutics. I've had the great pleasure of working in the area of heart medicine
Cardiol Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Feb 28, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers